Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
Evommune, Inc.NYSE: EVMN
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt rises 143.9% from a year ago
Short-term debt stood at $1.82M at the end of Q1 FY2026, up 143.9% from a year earlier and up 208.5% from the prior quarter.
Context
- Short-term debt amounted to 0.6% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Short-term debt increased in 1 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
What to watch
Whether short-term debt keeps rising in the next quarterly balance sheet after a +143.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 589K USD
- Year-over-year change
- -42.1%
- 2-year CAGR
- -12.5%
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 589K | -42.1% |
| FY2024 | 2024-12-31 | 1.02M | +32.4% |
| FY2023 | 2023-12-31 | 769K | — |
Short-term Debt vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 short-term debt of $1.82M is the 7th highest of the 10 companies compared; the peer median is $3.3M.
- Its year-over-year change of +143.9% is the 2nd highest of 4, against a peer median of +31.8%.
- Short-term debt amounts to 0.6% of total assets for EVMN, versus a peer median of 1.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $32.23M | +31.8% | — | 24.5% | |
FTREFortrea Holdings Inc. | Jun 2026 | $26M | -65.2% | — | 1.0% |
| Sep 2026 | $12.44M | +265.7% | — | 1.1% | |
| Mar 2026 | $3.94M | — | — | 1.3% | |
| Mar 2026 | $3.3M | — | — | 2.6% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $3.04M | — | — | 2.9% |
EVMNEvommune, Inc. | Mar 2026 | $1.82M | +143.9% | — | 0.6% |
CLYMClimb Bio, Inc. | Mar 2026 | $263K | — | — | 0.2% |
| Jun 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding EVMN) | $3.3M | +31.8% | — | 1.1% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.